Richard D. Truesdell, Jr.

Davis Polk advised the sole bookrunner in connection with the $168 million SEC-registered secondary offering of 12,000,000 shares of Class A common stock of Hostess Brands, Inc. by certain…

Davis Polk advised the underwriters in connection with the SEC-registered offering of 5,750,000 shares of common stock of Stemline Therapeutics, Inc. for total gross proceeds of…

Davis Polk advised the sole book-running manager and representative of the underwriters in connection with the $70 million follow-on offering of 741,750 shares of common stock of Kinsale…

Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by PTC Therapeutics, Inc. of its shares of common stock for up to an aggregate amount of $125…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $110 million initial public offering of 7,857,145 shares of common stock by…

Davis Polk advised the underwriters in connection with the SEC-registered offering by The Medicines Company of 5,227,273 shares of common stock for approximately $172.5 million, which…

Davis Polk advised the underwriters in connection with an SEC-registered offering of $1 billion aggregate principal amount of 2.950% notes due 2029 and $400 million aggregate principal…

Davis Polk advised the initial purchasers in connection with Rule 144A offerings by IAC FinanceCo 2, Inc. and IAC FinanceCo 3, Inc., wholly owned subsidiaries of IAC/InterActiveCorp (“IAC”)…

Davis Polk advised the sole bookrunner in connection with the $106.48 million SEC-registered secondary offering of 8,000,000 shares of Class A common stock of Hostess Brands, Inc. by…

Davis Polk advised the representatives of the several underwriters in connection with a $40 million initial public offering of common stock of Applied Therapeutics, Inc. Applied…